Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk liraglutide delayed

Executive Summary

FDA's review of Novo Nordisk's diabetes agent liraglutide will probably be delayed "by a couple of months" for an advisory committee review of the GLP-1 analogue, the company reports Sept. 5. The March 2, 2009 meeting is three weeks before liraglutide's user fee date (1"The Pink Sheet" DAILY, Aug. 8, 2008). Liraglutide may be subject to extra scrutiny after recent reports of pancreatitis from Amylin/Lilly's GLP-1 Byetta (exenatide)

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts